Subtopic Deep Dive
Hand-Foot Syndrome in Chemotherapy
Research Guide
What is Hand-Foot Syndrome in Chemotherapy?
Hand-foot syndrome (HFS), or palmar-plantar erythrodysesthesia, is a chemotherapy-induced skin toxicity characterized by painful erythema, swelling, and desquamation on palms and soles, primarily from capecitabine and doxorubicin.
HFS affects 20-60% of patients on capecitabine, leading to dose reductions or treatment discontinuation (Blum et al., 1999; 786 citations). Liposomal doxorubicin shows reduced HFS incidence compared to conventional forms (Uziely et al., 1995; 476 citations). Over 10 key papers document incidence, risk factors, and management in breast cancer trials.
Why It Matters
HFS impairs patient quality of life, causing pain that limits daily activities and reduces chemotherapy adherence, as seen in capecitabine trials for metastatic breast cancer (Blum et al., 1999; Bardia et al., 2006). It necessitates dose adjustments, impacting treatment efficacy (Rafiyath et al., 2012 meta-analysis). Effective management strategies, like those comparing liposomal vs. conventional doxorubicin, improve compliance and outcomes (Uziely et al., 1995; Rafiyath et al., 2012).
Key Research Challenges
Predicting HFS Incidence
HFS rates vary by agent and dose, with capecitabine causing 50%+ incidence in phase II trials (Blum et al., 1999). Risk factors like prior taxane exposure remain unclear (Blum et al., 2001). Patient-specific prediction models are lacking (Bardia et al., 2006).
Reducing HFS Toxicity
Conventional doxorubicin induces severe HFS, while liposomal forms show unique toxicity profiles (Uziely et al., 1995). Meta-analyses confirm lower cardiotoxicity but persistent skin risks with liposomes (Rafiyath et al., 2012). Prophylactic interventions need validation.
Managing Treatment Discontinuation
HFS leads to dose reductions in 20-30% of capecitabine patients, affecting survival (Blum et al., 1999; Fumoleau et al., 2003). Balancing antitumor efficacy with toxicity control challenges clinical decisions (Dy & Adjei, 2013).
Essential Papers
Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer
Joanne L. Blum, Stephen E. Jones, Aman U. Buzdar et al. · 1999 · Journal of Clinical Oncology · 786 citations
PURPOSE: Capecitabine is a novel, oral, selectively tumor-activated fluoropyrimidine carbamate. This large multicenter phase II trial tested the efficacy and safety of twice-daily oral capecitabine...
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
Hana Starobova, Irina Vetter · 2017 · Frontiers in Molecular Neuroscience · 597 citations
Chemotherapy-induced neuropathy is a common, dose-dependent adverse effect of several antineoplastics. It can lead to detrimental dose reductions and discontinuation of treatment, and severely affe...
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
E. Donnall Thomas, Henry Gómez, Rubi K. Li et al. · 2007 · Journal of Clinical Oncology · 482 citations
Purpose Effective treatment options for patients with metastatic breast cancer resistant to anthracyclines and taxanes are limited. Ixabepilone has single-agent activity in these patients and has d...
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
Beatrice Uziely, Susan Jeffers, Rut Isacson et al. · 1995 · Journal of Clinical Oncology · 476 citations
PURPOSE The purpose of our studies was to define the maximal-tolerated dose of liposomal doxorubicin (DOX-SL; Liposome Technology Inc, Menlo Park, CA), a doxorubicin formulation of polyethyleneglyc...
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients
Joanne L. Blum, V�ronique Dieras, Patricia Mucci Lo Russo et al. · 2001 · Cancer · 402 citations
The results of the current study demonstrate that capecitabine is an effective and well tolerated treatment in patients with taxane-refractory or taxane-failing metastatic breast carcinoma. In addi...
Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Grace K. Dy, Alex A. Adjei · 2013 · CA A Cancer Journal for Clinicians · 325 citations
Answer questions and earn CME/CNE Advances in genomics and molecular biology have identified aberrant proteins in cancer cells that are attractive targets for cancer therapy. Because these proteins...
Hand-Foot Syndrome After Dose-Dense Adjuvant Chemotherapy for Breast Cancer: A Case Series
Aditya Bardia, Charles L. Loprinzi, Matthew P. Goetz · 2006 · Journal of Clinical Oncology · 322 citations
Reading Guide
Foundational Papers
Start with Blum et al. (1999; 786 citations) for capecitabine HFS incidence in phase II trials, then Uziely et al. (1995; 476 citations) for liposomal doxorubicin toxicities.
Recent Advances
Study Bardia et al. (2006; 322 citations) on dose-dense chemotherapy HFS cases and Rafiyath et al. (2012; 295 citations) meta-analysis on anthracycline safety.
Core Methods
Phase II multicenter trials (Blum et al., 1999), toxicity meta-analyses (Rafiyath et al., 2012), and case series (Bardia et al., 2006) quantify incidence and risk factors.
How PapersFlow Helps You Research Hand-Foot Syndrome in Chemotherapy
Discover & Search
Research Agent uses searchPapers('hand-foot syndrome capecitabine') to find Blum et al. (1999; 786 citations), then citationGraph reveals forward citations like Bardia et al. (2006), and findSimilarPapers identifies related doxorubicin studies (Uziely et al., 1995). exaSearch uncovers meta-analyses on HFS risk.
Analyze & Verify
Analysis Agent applies readPaperContent on Blum et al. (1999) to extract HFS incidence rates (51%), verifyResponse with CoVe checks claims against abstracts, and runPythonAnalysis plots dose-toxicity curves from trial data using pandas. GRADE grading scores evidence as high for capecitabine HFS reporting.
Synthesize & Write
Synthesis Agent detects gaps in HFS prevention strategies across capecitabine papers, flags contradictions in liposomal doxorubicin toxicity (Uziely et al., 1995 vs. Rafiyath et al., 2012). Writing Agent uses latexEditText for review drafts, latexSyncCitations for 10+ papers, latexCompile for figures, and exportMermaid for HFS pathophysiology diagrams.
Use Cases
"Extract HFS incidence rates from capecitabine trials and plot by dose"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib on Blum 1999, Fumoleau 2003 data) → bar chart of 20-60% rates by agent/dose.
"Draft a review section on HFS management with citations"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Blum 1999, Uziely 1995) → latexCompile → PDF with formatted HFS table.
"Find code for modeling chemotherapy skin toxicity"
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for dose-response simulation from HFS datasets.
Automated Workflows
Deep Research workflow scans 50+ papers on capecitabine HFS (searchPapers → citationGraph → DeepScan), producing structured reports with incidence tables. DeepScan's 7-step analysis verifies toxicity claims (readPaperContent → CoVe → GRADE). Theorizer generates hypotheses on HFS risk factors from Blum et al. (1999) and Bardia et al. (2006).
Frequently Asked Questions
What is hand-foot syndrome?
Hand-foot syndrome is palmar-plantar erythrodysesthesia from chemotherapy like capecitabine, causing painful redness and peeling on hands/feet (Nagore et al., 2000).
What are common methods to study HFS?
Phase II trials assess incidence during capecitabine dosing (Blum et al., 1999), meta-analyses compare liposomal vs. conventional doxorubicin (Rafiyath et al., 2012).
What are key papers on HFS?
Blum et al. (1999; 786 citations) reports 51% incidence with capecitabine; Uziely et al. (1995; 476 citations) details liposomal doxorubicin toxicities.
What are open problems in HFS research?
Predicting patient-specific risk and validating preventives remain unsolved, as dose reductions persist despite management (Bardia et al., 2006; Dy & Adjei, 2013).
Research Chemotherapy-related skin toxicity with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Hand-Foot Syndrome in Chemotherapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers